Aileron therapeutics inc (ALRN)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Cash flows from operating activities:
Net loss

-29,369

-31,547

-22,604

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

155

218

129

232

325

Net amortization of premiums and discounts on investments

231

253

152

-

-

Net loss

-

-

-

-18,123

-12,878

Stock-based compensation expense

2,116

3,280

1,749

688

626

Change in deferred rent

-

11

11

18

21

Gain on sale of property and equipment

-5

-

-

-12

-

Write-off of deferred offering costs

-

-

-

1,500

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

206

117

764

75

109

Other assets

-1,318

-15

-

-

-

Other assets

-

-

-147

778

-

Accounts payable

-277

130

-241

1,215

-237

Operating lease liabilities

-370

-

-

-

-

Accrued expenses and other current liabilities

385

359

1,216

333

584

Net cash used in operating activities

-26,474

-27,926

-20,531

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-15,014

-11,710

Purchases of property and equipment

151

4,423

142

-

94

Purchases of investments

27,237

31,194

71,056

12,634

2,368

Proceeds from sales or maturities of investments

24,574

60,305

32,286

12,634

12,378

Net cash provided by (used in) investing activities

-2,814

24,688

-38,912

-

-

Cash flows from financing activities:
Proceeds from issuance of common stock, common warrants and pre-funded warrants, net of issuance costs

23,799

-

-

-

-

Proceeds from exercise of stock options

165

42

111

23

52

Increase in construction financing liability

-

2,473

-

-

-

Proceeds from initial public offering of common stock, net of commissions and underwriting discounts

-

-

52,313

-

-

Payments of initial public offering costs

-

-

2,304

180

1,320

Changes in restricted cash

-

-

-

25

-713

Net cash provided by (used in) investing activities

-

-

-

-25

10,629

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

471

32,143

-91

Net cash provided by financing activities

23,964

2,515

50,591

-

-

Net cash provided by financing activities

-

-

-

31,986

-1,359

Net decrease in cash, cash equivalents and restricted cash

-5,324

-723

-8,852

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

16,947

-2,440

Supplemental disclosure of non-cash financing activities:
Accretion of redeemable convertible preferred stock to redemption value

-

-

41

75

71

Issuance costs for redeemable convertible preferred stock included in accounts payable and accrued expenses

-

-

-

154

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

180

Capitalization of build-to-suit asset

-

2,869

-

-

-